Mobile help for opioid overdoses rolls into south suburbs with aid of Cook County $1M grant
Family Guidance Centers offers medications to people meant to counteract the effects of opioid overdoses from a clinic.
But whether it's access to transportation, child care needs or physical limitations, the nonprofit knows there are many people who need the lifesaving drugs but can't get to the clinic, said Ron Vlasaty, Family Guidance Centers' chief operating officer.
With the help of a Cook County grant of nearly $1 million, Vlasaty and county officials celebrated the rollout of a van that will bring the medications to more than two dozen south suburbs.
The program was announced Friday during a news conference outside the Posen Fire Department's headquarters, with the new van and another already in use by Family Guidance Centers parked outside.
Cook County Board President Toni Preckwinkle said while opioid overdose fatalities are 'trending in the right direction,' the problem is still of major concern.
'This crisis is everywhere,' Preckwinkle said. 'This is a challenge we have all over the country, not just in Cook County.'
With the rollout of the van, a refurbished ambulance, residents will no longer need to overcome transportation or access issues, she said.
We are 'able to deliver the care and services right where they are,' Preckwinkle said.
The van is equipped with a nurse, peer recovery support specialist and outreach staff to deliver care directly to communities most affected by the opioid crisis, according to the county.
It carries methadone, buprenorphine and naltrexone, FDA-approved medications for opioid and other drug overdoses. Family Guidance Centers' other van delivers naloxone, also known as Narcan, which can revive a person suffering an opioid overdose, Vlasaty said.
Posen police Chief William Alexander said opioid overdoses are one of the most urgent challenges faced by first responders.
'We are losing far too many lives to addiction and senseless violence,' Alexander said.
Preckwinkle said, with the rollout of the van, health care officials are working to operate in a backdrop of possible federal spending cuts that would help their efforts.
The nearly $1 million grant to Family Guidance Centers comes from the county's allocation of federal American Rescue Plan Act, a $1.9 trillion economic stimulus package passed in response to the COVID-19 pandemic.
'We see at the federal level a discouraging and alarming willingness to cut health care services,' Preckwinkle said, vowing Cook County will continue to provide services to those in need.
'If someone needs help we want to make sure they get it,' she said.
Deborah Sims, former Cook County commissioner for the 5th District, which includes many south suburbs, said 'this is a good day.'
Sims said that in delivering health care, agencies 'always want people to come to us.'
'If we can take it to the community it's always better for us and better for the residents,' she said.
The grant program is part of the county's Stronger Together initiative, a countywide effort focused on behavioral health equity, system coordination and the expansion of community-based care, according to the county.
The county grant to Family Guidance Centers is spread over three years, and the mobile unit will operate Monday through Friday.
Tom Nutter, chief behavioral health officer with the Cook County Office of Behavioral Health, said opioid addiction affects people from the very start, creating a dependency that requires increasing amounts of drugs.
For those with addictions, Nutter said their day 'begins with how will I get the drug and how will I pay for it?'
Nutter praised Family Guidance Centers for its work, saying they bring 'unquestionable dedication' to the job.
The Cook County Office of Behavioral Health was established by the county in 2023 to address the behavioral health needs of county residents, particularly those from historically marginalized and underserved populations.
Vlasaty said that the Family Guidance Centers operates 14 locations in Illinois, including eight in Cook County.
He said the Harvey clinic takes in residents from many south suburbs, but people can't always get to that location.
Vlasaty said the van will be able to go to patients' homes or central locations, such as village halls and police and fire stations, to distribute medications.
He said the nonprofit already distributes naloxone, which can help revive someone suffering an opioid overdose, to south suburban police departments through a smaller van it purchased with help of a previous county grant.
Family Guidance Centers also has a naloxone distribution point at Harvey's Pace bus station, established about a year ago. He said it needs to be refilled every couple of days and was done in conjunction with the county and Pace.
Vlasaty said Family Guidance Centers will put up informational posters at municipal buildings, liquor stores, gas stations and food pantries 'and wherever people congregate' to publicize the new mobile unit.
'We need to get the word out to where people are at to let them know this is available,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
15 minutes ago
- Epoch Times
Schools Across China Reportedly Isolate Students Over COVID Fears
Doctors and residents across China continue to report more infections and deaths as the latest wave of COVID-19 continues, portraying a far more severe situation than the Chinese regime is letting on. Schools in various provinces are reportedly suspending classes and placing students in quarantine, leading to growing concerns among the public of a return of lockdowns, according to information provided to the Chinese language version of The Epoch Times and on social media. A 'home quarantine notice,' issued by a primary school in Guangzhou and circulated by Chinese netizens on China's TikTok equivalent, Douyin, before being The notice said that a third-grade student was ordered to undergo quarantine for seven days after being diagnosed with COVID-19. After the quarantine period, health certificates from a clinic and community health service agency were required for the student to return to school. Schools in Shaanxi and Jiangsu also suspended classes after some students exhibited fevers, which were suspected to be COVID-19 infections. The Chinese communist regime's official data show that the COVID-19 infection rate doubled in April, with 168,507 cases, including 340 severe cases and nine deaths. The Chinese Center for Disease Control and Prevention (China CDC) said that infection rates in China's southern provinces were higher than that in the north. Related Stories 5/30/2025 5/31/2025 Chinese state media Xinhua reported on May 28 that, according to health officials, the upward trend of COVID-19 infections has slowed down, and in most provinces the epidemic has reached a peak or is on a downward trend. However, residents across the country told The Epoch Times the situation is far worse and that official data continue to not match their lived experience. Because of the CCP's history of covering up information and publishing unreliable data, including the underreporting of COVID-19 infections and related deaths since early 2020, accounts from local medical doctors and residents can offer valuable information for understanding the situation on the ground in the totalitarian country. Kang Hong, a doctor at a clinic in Guangzhou city in China's south who used a pseudonym for safety concerns, told The Epoch Times on May 29 that most of those infected with COVID-19 in this wave have been adults, although it has also affected children. 'Their symptoms are far more severe than the common cold,' he said, including the white-lung symptom often seen in COVID-19 patients. Kang said that most patients came to the clinic for symptoms of colds and fevers. He added that they are not being tested for COVID-19 'because hospitals in China had not conducted large-scale nucleic acid testing for a long time because it was worried about causing social panic.' Many patients are also unwilling to take a COVID-19 test, Kang said, 'because they know they are infected with the COVID-19 (based on their symptoms) and were unwilling to spend more than 100 yuan ($13.90) for testing.' Kang revealed that a doctor in a tertiary hospital in Guangzhou, where his daughter works, died from COVID-19 in recent days. 'It's a senior doctor who only got tested when his symptoms became serious, and the result was COVID-19,' Kang said. Kang added that although COVID-19 infections have increased, the local health bureau told the doctors that they do not need to report confirmed cases. Mr. Li, a resident of Guangzhou city who only gave his last name out of safety concerns, told The Epoch Times that there are many people around him who have had cold-like symptoms recently, including his whole family. Li said they were diagnosed with COVID-19 several times before, and believe their symptoms are another round of COVID-19. Mr. Guo, a resident in the adjacent Shenzhen city, told The Epoch Times that during the May Day holiday (May 1 to May 4), many people traveled and started to show cold symptoms that are likely COVID-19 afterwards. Meanwhile, residents in north China also reported a spike in COVID-19 infections. Liu Kun, the owner of a private clinic in Hohhot city in Inner Mongolia who gave the pseudonym for safety concerns, told The Epoch Times on May 30 that COVID-19 infections are ongoing, 'with many experiencing symptoms of coughing, sputum, vomiting and diarrhea.' He said there are many patients whose 'symptoms last for a long time—some even for months.' He predicted that based on the characteristics of this infectious disease, 'there may be an explosive growth in infections in June and July.' People wearing masks wait at an outpatient area of the respiratory department of a hospital in Beijing, China, on Jan. 8, 2025. JADE GAO/AFP via Getty Images Mr. Xu, a resident in Benxi city of Liaoning Province who only gave his surname out of safety concerns, told The Epoch Times that some of his friends and relatives have recently caught colds. 'We have already realized that it may be COVID-19 caused by a mutated virus. The symptoms have been dragging on and not getting better. It cannot be cured by medicine at all.' He added that there have been sudden deaths, especially concentrated around people in their 40s and 50s. The infections have also been rapidly spreading in Shanxi Province, Mr. Luo, a resident of Changzhi city who only gave his surname, told The Epoch Times. 'My family members—including my wife, daughter, son-in-law, and granddaughter—have all been infected,' he said. Fear of Zero-COVID Restrictions The school suspensions and quarantines have heightened public concern that the regime's draconian zero-COVID restrictions employed from 2020 to the end of 2022—during which communities were locked down, mass testing was mandatory, travel was restricted, and residents were forcefully sent to quarantine centers—could make a comeback. Dr. Jonathan Liu, director of Liu's Wisdom Healing Centre and a professor at Canada Public College, told The Epoch Times on May 30 that although mainland China is experiencing another wave of COVID-19 infections, the official data hasn't indicated a serious spread that requires the lockdown of cities. 'Following the continuing strategy of concealment, the Chinese regime does not want to shut down the cities or implement the zero-COVID policy at the moment because that will seriously affect its economic development. Now, stimulating economic development is the regime's top priority,' Liu said. Sean Lin, assistant professor in the Biomedical Science Department at Feitian College and former U.S. army microbiologist, shares a similar assessment. 'The authorities won't immediately adopt the lockdown measure because they also know that if they implement the strict zero-COVID policy, it will cause a huge backlash from the public,' Lin told The Epoch Times on May 30. 'So the government is now building mobile cabin hospitals or temporary isolation facilities in various regions to quietly take people away. There may not be major changes in policy announced to the public,' he said. The Chinese language edition of The Epoch Times reported earlier this year that, according to insiders in some parts of China, local governments were building large scale mobile cabin hospitals to quarantine patients with respiratory infections, including COVID-19, such as in Urumqi in Xinjiang region and in several provinces. Employees work at a makeshift hospital that will be used for Covid-19 coronavirus patients in Guangzhou, in China's eastern Guangdong province on April 11, 2022. (Photo by AFP) / China OUT Lin said that some places may have adopted measures to let people stay at home for quarantine 'but it will not turn into a large-scale policy unless the regime is unstable and the authorities have to take such measures. It has not reached that point yet.' The China CDC has yet to release its COVID-19 data for May but did update its weekly influenza report, in which the number of infections increased significantly this week. According to the weekly influenza report for epidemiological week 21 (May 19 to 25), released May 29, a total of eight influenza-like outbreaks have been reported nationwide. In comparison, only one influenza-like outbreak was reported nationwide in week 20 and no influenza-like outbreaks were reported in week 19. Lin said that the authorities continue to cover-up real COVID data in China. 'The people do not know the real situation and the severity of the wave of outbreak, especially the severity rate and mortality rate. The authorities don't tell the people.' He said that China's situation is more complicated and severe, as 'it involves multiple respiratory pathogens co-circulating and co-infections, with three or four respiratory pathogens infecting at the same time, not just this NB.1.8.1 strain. But the officials have not revealed the real situation, so I think it is difficult for the international community to understand.' NB.1.8.1 Chinese health authorities announced on May 23 that Omicron variant NB.1.8.1 is currently the primary variant spreading across China, as detection of the variant increased in the international community. NB.1.8.1 is a sixth-generation sub-branch of the XDV variant. 'The current data does not show that the NB1.8.1 variant has a significant breakthrough in pathogenicity, but it has an almost 1.8-fold improvement in immune escape capability. If it replaces the previous dominant variant that caused COVID-19, it's because its transmission ability is enhanced,' Lin told The Epoch Times. He pointed out that new COVID variants have frequently emerged in the past three years. 'Often new strains quickly replace old ones to be the dominant one. This has become routine.' A person receives a COVID-19 vaccine at Los Angeles International Airport in Los Angeles, Calif., on Dec. 22, 2021. Frederic J. Brown/AFP via Getty Images The World Health Organization (WHO) has As the wave of infections in China continues, However, Lin said there is no sign of a ban of travelers or flights from China by other countries 'because the WHO does not have accurate data from China.' 'According to the current monitoring of countries around the world, there has not been a rapid, large-scale increase in infections like in the one in 2020.' Lin said that because the Chinese regime does not reveal true data, 'it's not possible to track virus spreading routes.' 'This also brings about a greater danger,' he said. 'China often covers up many things until they can no longer be covered up. When they come out, the situation is already quite serious and may be out of control. This is actually the biggest concern.' Luo Ya, Fang Xiao, and Xiong Bin contributed to this report.
Forbes
2 hours ago
- Forbes
Subtle Differences Emerge Between FDA And CDC On COVID Vaccine Advice
An illustration picture shows vials with Covid-19 vaccine stickers attached and syringes with the ... More logo of the company Novavax. (Photo by JUSTIN TALLIS / AFP) (Photo by JUSTIN TALLIS/AFP via Getty Images) In a major policy shift last month, Food and Drug Administration officials proposed requiring new clinical trial research with respect to the effectiveness of COVID-19 vaccines in healthy people under 65, including pregnant women, before issuing an updated approval for a broader population. At the same time, in an update to its immunization schedule posted May 29th, the Centers for Disease Control and Prevention include the option of COVID-19 vaccines for healthy children and pregnant women. Based on the language used by CDC, it suggests the agency aims for a shared decision-making approach in which individuals consult with their doctor prior to getting a shot. We witnessed a preview of the new FDA approach when the agency made an unusual decision to limit the approval of the nation's only non-mRNA coronavirus vaccine, Novavax's nuvaxovid, for use only in adults 65 and older or those 12 to 64 who have at least one health problem that puts them at increased risk from COVID-19. To be indicated for a broader population, the FDA plans to require that vaccine makers conduct booster trials to demonstrate effectiveness in people under 65 or without certain risks. These trials could take a year to complete, according to a STAT report. As such, it's not something that can be accomplished prior to the autumn, even if Novavax, Pfizer, or Moderna, wished to pursue this pathway. Similar to annual flu shots, which adapt to new strains, COVID-19 boosters update immunity to target evolving variants. Data from several years of booster campaigns show lower hospitalization and death rates for boosted individuals compared to unvaccinated people or those who haven't gotten boosters. This particularly applies to the vulnerable subpopulations, stratified by age and underlying health conditions. The COVID-19 vaccines, both mRNA and non-mRNA, are recommended for anyone who is over 65 or who has a medical condition that can increase the risk of severe illness or death. Underlying conditions include, among other things, obesity, 'physical inactivity,' diabetes, clinical depression and being immunocompromised. It's estimated that between 100 and 200 million Americans will still be eligible for vaccination due to having such health issues. Nevertheless, this raises questions for people who don't have underlying health conditions and are under 65 but would like to get a COVID-19 shot this fall. The FDA and CDC appear to differ subtly in terms of their current advice for healthy individuals under 65. Is it possible for these folks to obtain a jab at the pharmacy with no questions asked? Or will they have to go to their doctor and be granted de facto permission to get the shot? Perhaps equally important, will their insurer pay for it? As the New York Times explains, insurance companies may serve as the 'gatekeepers by demanding medical documentation of an underlying condition before agreeing to cover the cost.' The out-of-pocket cost to patients could be as much $140 a shot. Top FDA officials Prasad and Makary advocate an 'evidence-based' approach to COVID-19 vaccination. They also write of aligning policy with Europe. Indeed, in most instances, European public health authorities have adopted a targeted approach that aims at ensuring the elderly and those with underlying health conditions get boosted. This means that outreach campaigns in European countries only target subpopulations for which the vaccine is recommended by the respective public health authority. This is unlike the universal recommendations previously issued by the CDC that didn't differentiate by age or risk factors. However, the European agencies in charge of vaccine approval, the EMA and MHRA, haven't suggested marketing authorization changes, such as narrowing the indication based on age, for any of the approved COVID-19 vaccines.
Yahoo
2 hours ago
- Yahoo
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated, cancer experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called Selective Estrogen Receptor Degraders (SERDS) block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor (157 patients) or continue with standard treatment plus a placebo (158 patients). The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Separately, adding AstraZeneca's immunotherapy durvalumab to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped extend the time patients had without cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested durvalumab, sold under the brand Imfinzi, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. Patients in the durvalumab plus FLOT arm experienced a 29% better event-free survival than those who received the chemotherapy regimen. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Jarnigan of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were published on Sunday in the New England Journal of Medicine.
